Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.
Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the ways in which coronavirus reshaped Italian hospitals, mistakes made, and lessons learned. Filmed April 15, 2020.
William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?
Recorded April 24, 2020.
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24, 2020.
